ClinicalTrials.gg
RecruitingNCT07076849ProMomsUpdated Nov 2, 2026

Probiotic Supplementation in Optimizing Iron and Hematological Status Among Pregnant Females

A Phase 2 interventional study of Lactiplantibacillus plantarum 299v and Placebo Capsule(s) in Iron Deficiency (ID) and Pregnancy, sponsored by University of Illinois Chicago. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of Illinois Chicago · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 2, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Iron Deficiencies with a site in United States — 16 open to participants now, 20 under way, 4 of them phase 3. Iron Deficiencies · United States.

Planned enrollment
10th of 63
250 · median 89
Started
2026
with 7 others
Phase 2
8 of 82
2 open now
Primary completion
2030-10
later than 19 of 19 live
Registered
70th of 82
by date

Among the 82 studies in Iron Deficiencies with a site in United States, this one is the 10th largest by planned enrollment of the 63 interventional ones that give a count, is one of 8 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 19 of the 19 other live ones, and was the 70th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

16 of the 82 studies in Iron Deficiencies with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Iron Deficiencies with a site in United States, or all of them as a file.
02

Study summary

Maternal iron deficiency (ID) and iron deficiency anemia (IDA) is associated with maternal and infant mortality, spontaneous preterm birth, maternal postpartum hemorrhage, and neurocognitive defects in the neonate. Therefore, preventing maternal IDA in at-risk women is critical. The standard approach to improving iron status in pregnancy (i.e., oral iron supplements) is suboptimal and gastrointestinal discomforts associated with this approach (i.e., constipation) impairs adherence. The incidence of ID (18%) and IDA (5%) in pregnant populations suggest alternative interventions are needed to optimize iron status in pregnancy. There is increasing evidence that consuming the probiotic Lactoplantibacillus plantarum 299v (LP299V®) can enhance dietary non-heme iron absorption by changes in the composition and metabolic patterns of gut microbiota that reduce intestinal pH, enhance mucin production and favor an anti-inflammatory milieu. This immunomodulatory effect may be important because inflammation stimulates hepatic production of hepcidin, a master regulator of systemic iron homeostasis, which inhibits iron flow into circulation from diet and body stores. Further, the effects of LP299V® may extend to the placenta. The investigators' team showed previously that maternal iron deficiency is associated with changes to placental iron metabolism with more iron sequestered in the placenta and less iron transferring to the fetus. Given its positive effects on maternal iron status, the investigators surmise that LP299V® supplementation will result in higher placenta protein expression of iron transporters, transferrin receptor-1 and ferrroportin-1, and lower placental iron accumulation/content. The primary goal of this study is to test the efficacy of this low-cost, safe, innovative approach to optimizing maternal iron status in individuals at risk for ID in pregnancy [Hb 11.0 - 11.9 g/dL (first trimester) and Hb 10.5 - 11.5 g/dL (second trimester) based on new OB clinical complete blood count (CBC) results obtained from the EHR] from 10-16 weeks gestational age (GA) until the time of labor. The investigators will also test the effects on neonatal (cord blood) iron status and (cord blood + newborn heel stick) Hb at birth and determine the effect of maternal LP299V® supplementation on the maternal gut microbiome, hepcidin-ferroportin axis and placenta iron and placenta transport of iron as its primary mechanisms of action. Finally, the investigators will explore the effect of maternal LP299V® supplementation on infant neurodevelopment at birth. This study is an essential first step toward evaluating if twice daily oral LP299V® is an efficacious, safe, inexpensive, and scalable clinical strategy for the prevention of maternal ID and its related complications in at-risk women.

03

Conditions studied

  • Iron Deficiency (ID)
  • Pregnancy

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • singleton naturally conceived pregnancy;
  • at risk of IDA [ 11.0 - 13.0 g/dL (first trimester) and Hb 10.5 - 12.5 g/dL (second trimester) based on new OB clinical complete blood count (CBC) results obtained from the EHR;
  • 18 - 45 years old;
  • 10-22 weeks GA;
  • fluency in English to provide consent and complete study procedures;
  • ability to provide consent;

Exclusion criteria

Exclusion Criteria:

  • IDA or other nutritional anemia (i.e., diagnosed or suspected B12 or folate deficiency) based on new OB blood work that includes MCV and MCH to characterize the anemia;
  • recent blood transfusion;
  • disorder (e.g., rheumatoid arthritis);
  • inflammatory bowel disease;
  • oral or IV antibiotic use within 2 months;
  • previous spontaneous preterm birth;
  • history of bariatric surgery;
  • malabsorptive disease;
  • current hyperemesis;
  • current eating disorder;
  • hematologic disorder or trait carrier (e.g., hemochromatosis, β-thalassemia);
  • current tobacco, alcohol or illicit drug use (Excluding marijuana).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Lactiplantibacillus plantarum 299v (LP299V®)

    Probiotic

    Dietary Supplement: Lactiplantibacillus plantarum 299v

  • Placebo comparator
    Control

    Placebo capsule

    Other: Placebo Capsule(s)

Interventions

06

What researchers measure

Primary outcomes

  1. Maternal hemoglobin from complete blood count (CBC) with differential

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

Secondary outcomes

  1. Maternal iron deficiency anemia (IDA)

    Hb \<10.5 g/dL during second trimester and Hb \<11 g/dL during third trimester

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  2. Complete blood count (CBC) with differential (WBC, RBC, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  3. Maternal serum ferritin

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  4. Maternal serum iron

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  5. Maternal sTfR

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  6. Maternal total body iron (TBI)

    (TBI (mg/kg) = - \[log(TfR/ferritin ratio) - 2.8229\]/0.1207)

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  7. Maternal hepcidin

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  8. Maternal erythropoietin (EPO)

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  9. Maternal circulating cytokines (interleukin-6 (IL-6), GM-CS, IL-2, IL-4, IL-8, IL-10, TNFα, and IFNγ

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  10. Maternal C-reactive protein (CRP)

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  11. Maternal Erythroferrone (ERFE)

    Venous blood draw

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  12. Maternal Erythroferrone (ERFE) Cord Complete blood count (CBC) with differential (WBC, RBC, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)

    Cord blood draw

    Time frame: delivery

  13. Cord serum ferritin

    Cord blood draw

    Time frame: delivery

  14. Cord serum iron

    Cord blood draw

    Time frame: delivery

  15. Cord sTfR

    Cord blood draw

    Time frame: delivery

  16. Cord total body iron (TBI)

    (TBI (mg/kg) = - \[log(TfR/ferritin ratio) - 2.8229\]/0.1207)

    Time frame: delivery

  17. Newborn heel stick

    Blood spot

    Time frame: After delivery before baby released home

  18. Placenta iron transporter (FPN-1 and TFR-1)

    Western blot

    Time frame: delivery

  19. Placenta iron quantification

    Immunohistochemistry

    Time frame: delivery

  20. Placenta tissue iron concentration

    Inductively coupled plasma-mass spectrometry (ICP-MS)

    Time frame: delivery

  21. Fecal abundance of A. muciniphila

    Quantitative polymerase chain reaction (qPCR)

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)

  22. Shot-gun sequencing and analysis (taxonomy and functional profiling)

    MetaPhlAn4 and HUMAnN 2.0

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)

  23. Microbial mucin degrading enzymes

    CaZymes

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)

  24. Stool pH

    pH probe

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)

  25. Adverse pregnancy outcomes post-treatment and at delivery (clinical- EMR)

    Adverse pregnancy outcomes post-treatment and at delivery (clinical-EMR)

    Time frame: delivery

  26. Probiotic acceptance and tolerability

    Daily capsule adherence Reported adverse health effects

    Time frame: 10-22 weeks GA, 14-20 weeks GA, 18-24 weeks GA, 22-28 weeks GA, 26-32 weeks GA, 30-36 weeks GA, 34-40 weeks GA, 38-40 weeks GA

  27. Auditory Brainstem Response (ABR) testing

    Interpeak latency I-V

    Time frame: -3 days postpartum

Other outcomes

  1. Habitual and recent dietary intake

    Food frequency (baseline only) questionnaire and 24-hour diet recall

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)

  2. Physical activity

    Self-report questionnaire

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)

  3. Infant characteristics (clinical-EMR)

    Infant sex, weight, gestational age (clinical-EMR)

    Time frame: delivery

  4. Pre-pregnancy body mass index (BMI)

    Self-report (confirmed by clinical-EMR, if possible) BMI will be calculated as kg/m2

    Time frame: Up to 6 months before pregnancy

  5. Gestational weight gain

    Gestational weight gain

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)

  6. Gut microbiome factors

    Questionnaire related to allergies, diet, travel, and environment

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)

  7. Presence of probiotic strain in stool

    Quantitative polymerase chain reaction (qPCR)

    Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Oct 2030, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 22, 2025
StartActual
Feb 1, 2026
Primary completionEst.
Oct 30, 2030
CompletionEst.
Nov 30, 2030
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • Editedat risk of IDA [Hb 11.0 - 1113.90 g/dL (first trimester) and Hb 10.5 - 1112.5 g/dL (second trimester) based on new OB clinical complete blood count (CBC) results obtained from the EHR;
  • Edited10-1622 weeks GA;
  • Removedand ownership of a smartphone (currently more than 90% of our patient population at the CWH).
Nov 2, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameMaternal hemoglobin from complete blood count (CBC) with differential10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Nov 2, 2026
Secondary outcomes
21 time frame changed
What changed in the outcomes
  • Time frameMaternal iron deficiency anemia (IDA)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameComplete blood count (CBC) with differential (WBC, RBC, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameMaternal serum ferritin10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameMaternal serum iron10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameMaternal sTfR10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameMaternal total body iron (TBI)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameMaternal hepcidin10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameMaternal erythropoietin (EPO)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameMaternal circulating cytokines (interleukin-6 (IL-6), GM-CS, IL-2, IL-4, IL-8, IL-10, TNFα, and IFNγ10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameMaternal C-reactive protein (CRP)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameMaternal Erythroferrone (ERFE)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameFecal abundance of A. muciniphila10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
  • Time frameShot-gun sequencing and analysis (taxonomy and functional profiling)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
  • Time frameMicrobial mucin degrading enzymes10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
  • Time frameStool pH10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
  • Time frameProbiotic acceptance and tolerability10-16 weeks GA, 14-20 weeks GA, 18-24 weeks GA, 22-28 weeks GA, 26-32 weeks GA, 30-36 weeks GA, 34-40 weeks GA, 38-40 weeks GA → 10-22 weeks GA, 14-20 weeks GA, 18-24 weeks GA, 22-28 weeks GA, 26-32 weeks GA, 30-36 weeks GA, 34-40 weeks GA, 38-40 weeks GA
  • Time frameother outcomeHabitual and recent dietary intake10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
  • Time frameother outcomePhysical activity10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
  • Time frameother outcomeGestational weight gain10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
  • Time frameother outcomeGut microbiome factors10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
  • Time frameother outcomePresence of probiotic strain in stool10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
Nov 2, 2026
Sponsor
University of Illinois at Chicago→University of Illinois Chicago
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Eligibility 2 inclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Editedat risk of IDA [Hb 11.0 - 1113.90 g/dL (first trimester) and Hb 10.5 - 1112.5 g/dL (second trimester) based on new OB clinical complete blood count (CBC) results obtained from the EHR;
    • Edited10-1622 weeks GA;
    • Removedand ownership of a smartphone (currently more than 90% of our patient population at the CWH).
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameMaternal hemoglobin from complete blood count (CBC) with differential10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    Secondary outcomes 21 time frame changed
    What changed in the outcomes
    • Time frameMaternal iron deficiency anemia (IDA)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameComplete blood count (CBC) with differential (WBC, RBC, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameMaternal serum ferritin10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameMaternal serum iron10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameMaternal sTfR10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameMaternal total body iron (TBI)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameMaternal hepcidin10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameMaternal erythropoietin (EPO)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameMaternal circulating cytokines (interleukin-6 (IL-6), GM-CS, IL-2, IL-4, IL-8, IL-10, TNFα, and IFNγ10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameMaternal C-reactive protein (CRP)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameMaternal Erythroferrone (ERFE)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameFecal abundance of A. muciniphila10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
    • Time frameShot-gun sequencing and analysis (taxonomy and functional profiling)10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
    • Time frameMicrobial mucin degrading enzymes10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
    • Time frameStool pH10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
    • Time frameProbiotic acceptance and tolerability10-16 weeks GA, 14-20 weeks GA, 18-24 weeks GA, 22-28 weeks GA, 26-32 weeks GA, 30-36 weeks GA, 34-40 weeks GA, 38-40 weeks GA → 10-22 weeks GA, 14-20 weeks GA, 18-24 weeks GA, 22-28 weeks GA, 26-32 weeks GA, 30-36 weeks GA, 34-40 weeks GA, 38-40 weeks GA
    • Time frameother outcomeHabitual and recent dietary intake10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
    • Time frameother outcomePhysical activity10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
    • Time frameother outcomeGestational weight gain10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
    • Time frameother outcomeGut microbiome factors10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
    • Time frameother outcomePresence of probiotic strain in stool10-16 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3) → 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
    Sponsor University of Illinois at Chicago→University of Illinois Chicago
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07076849
Lead sponsor
University of Illinois Chicago
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Feb 1, 2026
Primary completion
Oct 30, 2030 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Nov 2, 2026

Study contacts

Mary Dawn Koenig, PhD, RN, CNM
Contact
marydh@uic.edu
312-996-7982

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactiplantibacillus plantarum 299V

Start the discussion